

Column May 2014

New indications

Abraxane (**nanoparticle albumin bound paclitaxel**), in combination with carboplatin, is now indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation.

Safety related changes

Azarga (**brinzolamide, timolol**) use is now contraindicated in the presence of sino-atrial block and sick sinus syndrome.

Chloromycetin Ear Drops (**chloramphenicol**) should be used with caution in patients who have been identified as having an individual or family history of blood disorders.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

